Advances in Non-alcoholic Fatty Liver Disease: Pathophysiology, Diagnosis, and Emerging Therapies

A special issue of Life (ISSN 2075-1729).

Deadline for manuscript submissions: 26 April 2025 | Viewed by 635

Special Issue Editors


E-Mail Website
Guest Editor
First Department of Surgery, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece
Interests: general surgery; surgical oncology; hepato-pancreato-biliary (HPB) surgery; non-alcoholic fatty liver disease (NAFLD)
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
First Department of Surgery, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece
Interests: esophageal cancer; gastric cancer; pancreatic cancer; immunotherapy; personalized medicine; surgery; medical education
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide, correlating strongly with the increasing prevalence of metabolic syndrome. First recognized in the 1980s, NAFLD encompasses a spectrum ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), which can progress to cirrhosis and hepatocellular carcinoma. Despite its widespread impact, the pathophysiological mechanisms and optimal management strategies for NAFLD are not yet fully understood, necessitating ongoing research and clinical innovation.

This Special Issue aims to provide a platform for the dissemination of the latest research findings and clinical advancements in NAFLD. Our goal is to enhance our understanding of the disease’s etiology, improve diagnostic accuracy, and explore novel therapeutic options. By fostering a multidisciplinary dialogue, this Special Issue seeks to bridge gaps between basic science, clinical practice, and public health approaches to tackle NAFLD comprehensively.

We are particularly interested in studies elucidating the molecular and genetic underpinnings of NAFLD, the role of the gut–liver axis, and the impact of comorbid conditions such as diabetes and cardiovascular disease. Advances in non-invasive diagnostic techniques, including imaging and biomarkers, are also a key focus. Additionally, we seek submissions focused on innovative therapeutic approaches, encompassing lifestyle interventions, pharmacotherapy, and surgical treatments.

We invite original research articles, comprehensive reviews, and meta-analyses addressing the aforementioned topics. Submissions should offer new insights into the mechanisms of NAFLD, present data on novel diagnostic and therapeutic strategies, or provide critical evaluations of current knowledge and future directions.

Dr. Ioannis Katsaros
Dr. Dimitrios Schizas
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • non-alcoholic fatty liver disease (NAFLD)
  • metabolic dysfunction-associated fatty liver disease (MAFLD)
  • steatohepatitis
  • metabolic syndrome
  • insulin resistance
  • apoptosis/cell death

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers

This special issue is now open for submission.
Back to TopTop